Prospective comparison of two enzyme-linked immunosorbent spot assays for the diagnosis of Lyme neuroborreliosis.
Commercial cellular tests are used to diagnose Lyme borreliosis, but studies on their clinical validation are lacking. This study evaluated the utility of an in-house and a commercial enzyme-linked immunosorbent spot (ELISpot) assay for the diagnosis of Lyme neuroborreliosis. Prospectively, peripheral blood mononuclear cells (PBMCs) were isolated from patients and controls and analysed by using an in-house Borrelia ELISpot assay and the commercial LymeSpot assay. Borrelia burgdorferi B31 whole cell lysate and a mixture of outer surface proteins were used to stimulate the PBMCs and the numbers of interferon-gamma-secreting T cells were measured. Results were evaluated using receiver operating characteristic (ROC) curve analysis. Eighteen active and 12 treated Lyme neuroborreliosis patients, 10 healthy individuals treated for an early (mostly cutaneous) manifestation of Lyme borreliosis in the past, and 47 untreated healthy individuals were included. Both assays showed a poor diagnostic performance with sensitivities, specificities, positive and negative predictive values ranging from 44.4% to 66.7%, 42.0% to 72.5%, 21.8% to 33.3%, and 80.5% to 87.0%, respectively. The LymeSpot assay performed equally poor when the calculation method of the manufacturer was used. Both the in-house and the LymeSpot assay are unable to diagnose active Lyme neuroborreliosis nor to monitor antibiotic treatment success.